Agencies-Gaza post
Clinical trials of medicine developed by Volgograd University scientists for the treatment of diabetes and obesity will begin in 2022, according to Professor Ivan Torenkov, Corresponding Member of the Russian Academy of Sciences.
The professor emphasized that clinical trials for the new medicine “Dipyarone” for the treatment of diabetes and obesity, which is unparalleled in the world, will begin this year.
He added that taking this treatment helps to normalize the level of glucose in the blood and is a means of increasing the effectiveness of treating diabetes, metabolic syndrome, and obesity. It can be used as a stand-alone treatment for type 1 diabetes in the early stages.
“This medicine is unique and original in its class, and has no equal in the world,” the professor said.
This drug stimulates the production of incretins (intestinal hormones), which, after eating, enables the production of these hormones, which in turn stimulates the secretion of insulin.
It accelerated the transmission of this mechanism is disrupted, as in type 2 diabetes, where incretin production does not provide the necessary amount of insulin secretion, sugar remains in the blood.
